Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) and Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Agios Pharmaceuticals and Voyager Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agios Pharmaceuticals | 1 | 4 | 5 | 1 | 2.55 |
| Voyager Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
Agios Pharmaceuticals presently has a consensus target price of $41.75, indicating a potential upside of 31.62%. Voyager Therapeutics has a consensus target price of $16.50, indicating a potential upside of 570.73%. Given Voyager Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Agios Pharmaceuticals.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agios Pharmaceuticals | $98.34 million | 19.26 | -$412.78 million | ($7.01) | -4.52 |
| Voyager Therapeutics | $40.37 million | 3.75 | -$119.72 million | ($1.80) | -1.37 |
Voyager Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
48.0% of Voyager Therapeutics shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Agios Pharmaceuticals and Voyager Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agios Pharmaceuticals | -418.24% | -35.67% | -33.06% |
| Voyager Therapeutics | -312.63% | -57.92% | -45.00% |
Volatility and Risk
Agios Pharmaceuticals has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
Summary
Voyager Therapeutics beats Agios Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.